New immunotherapy trial for type 1 diabetes ;
The search for a treatment for diabetes type 1 (DM1) – which affects more than 400,000 people in the UK – intensified with the start of a new phase of a clinical trial at guy’s Hospital in London.
The new immunotherapy treatment, called MultiPepT1De, is being developed to address the autoimmune attack that leads to the development of type 1 diabetes .
Type 1 diabetes is an autoimmune disease in which the pancreas cells that produce insulin are destroyed by the immune system. The new therapy, MultiPepT1De, will use protein fragments, known as peptides, in an effort to stop this process by “turning off” the specific autoimmune attack , and hopefully prevent further destruction of pancreatic cells.
In laboratory tests, MultiPepT1De is more powerful than the first generation of treatment tested last year and is designed to benefit a greater proportion of people with type 1 diabetes than its predecessor.
MultiPepT1De was developed with funding from the Wellcome Trust researchers at King’s College London who work at the National Institute for Health Research (NHRI) Biomedical Research Centre (BRC) at Guy and St Thomas’ and Kings College London.
MultiPepT1De was tested on 24 people with type 1 diabetes for fall 2016 and the study team is the hope of positive results based on their previous findings showing that the first generation of MultiPepT1De, called MonoPepT1De, is safe and well tolerated, with some evidence of positive effects on T1D patients.
Professor Mark Peakman, principal investigator at the BRC and Chief of the Division of Diabetes and Nutritional Sciences at the King said: “We are very anxious to see the results of this new trial What we are doing is a big step. forward in medicine precision, taking a number of patients with a particular disease and genetic background and give them an immunotherapy designed in the laboratory specifically for them. Obviously we have to wait until we have the complete results of the test before we know if successful, but at this stage we have hope. ”
Dr. Stephen Caddick, Director of Innovations at the Wellcome Trust, said: “Type 1 diabetes is a very serious disease that usually requires lifelong treatment with insulin therapy, but this promising new form of ‘immunotherapy ‘could be set to change that. by the conversion of the immune system to prevent attack the insulin-producing cells may be possible to slow the progression of the disease or even stop it in its tracks. If this approach is given good results in larger studies which it has the potential to transform the lives of people with type 1 diabetes. ”
In the last decade, the number of people in the UK with diabetes has increased by about 65 percent to 4 m, according to Diabetes UK, with around 400,000 adults and children now suffering from diabetes type 1 diabetes treatment is estimated to cost the NHS around £ 10 billion per year.
MultiPepT1De is based on an area of study called peptide immunotherapy, which is currently being applied to a number of other diseases, such as allergies and multiple sclerosis.
Jeremy Hunt, Secretary of State for Health, said: “This exciting new treatment has the potential to transform the lives of thousands of patients across the UK living with type 1 diabetes Thanks to our strong economy we invested over £ 1 billion. every year in health research, which helps us to lead the world in medical innovation and give NHS patients the latest treatments last generation. ”
This article was originally published on medicalxpress, Read the original article
Posted in: Diabetes